U.S. Insurance Stock News

RH (RH) has drawn fresh attention after appointing long-time manufacturing partner executive Veronica Schnitzius to lead manufacturing and sourcing, alongside the return of real estate veteran David Stanchak to oversee expansion and asset monetization. See our latest analysis for RH. Those leadership changes arrive after a sharp reset in investor expectations, with the 30 day share price return of RH at a 21.04% decline and the 1 year total shareholder return down 44.62%. This points to...

Green Plains (GPRE) has drawn fresh attention as investors reassess its role in low carbon fuels, with recent returns over the month and past 3 months prompting closer scrutiny of its fundamentals. See our latest analysis for Green Plains. At a share price of $16.89, Green Plains has seen a 30 day share price return of 23.02% and a 90 day share price return of 71.47%. Its 1 year total shareholder return of 247.53% contrasts with weaker 3 and 5 year total shareholder returns, suggesting strong...

Marex Group plc recently issued earnings guidance for the first quarter ended March 31, 2026, forecasting revenues between US$667 million and US$697 million, compared with US$467 million in the same period of 2025. This guidance implies a sharp year-on-year uplift in expected quarterly revenue, hinting at materially stronger client activity and business momentum across Marex’s platform. We’ll now examine how this significantly higher first-quarter 2026 revenue outlook influences Marex...

In March 2026, Tarsus Pharmaceuticals announced that its partner Grand Pharmaceutical Group secured National Medical Products Administration approval in China for TP-03 (XDEMVY) to treat Demodex blepharitis, triggering a US$15,000,000 milestone payment to Tarsus and confirming TP-03 as the first approved therapy addressing the disease’s root cause in Greater China. This approval not only validates TP-03’s clinical and regulatory profile outside the U.S., but also opens a new revenue stream...

Monte Rosa Therapeutics, Inc. recently reported a fourth-quarter 2025 net loss of US$46.14 million and entered a supply agreement with Johnson & Johnson to evaluate its investigational molecular glue degrader MRT-2359 in combination with ERLEADA in a planned Phase 2 study for metastatic castration-resistant prostate cancer. This collaboration, together with positive early data for MRT-2359 presented at the 2026 ASCO GU Cancers Symposium, highlights growing external interest in Monte Rosa’s...

Earlier this month, UFP Packaging, a division of UFP Industries, introduced Slot-Lock and Clamp-Lock 100 industrial crate systems that enable nail-gun-free, pneumatic-free assembly, emphasizing safer construction, reusability, and reduced waste across sectors from aerospace to infrastructure. This product launch highlights UFP’s push into higher-value engineered packaging solutions that aim to improve customer safety and efficiency while expanding its differentiated, customizable...

Celcuity (CELC) has been in focus after the FDA accepted its New Drug Application for gedatolisib with priority review, while management simultaneously accelerates commercial preparation ahead of a potential launch. See our latest analysis for Celcuity. The share price has been volatile around these updates, with a 1 day share price return of negative 7.66% and a 30 day share price return of negative 5.09%. However, the 1 year total shareholder return is very large and indicates that longer...

Adecoagro S.A. recently filed a US$21.50 million shelf registration for 1,727,040 common shares tied to an ESOP, following fourth-quarter 2025 results showing sales of US$415.94 million and a net loss of US$14.85 million. The combination of higher quarterly sales but a swing to loss, alongside potential equity issuance for employee ownership, raises fresh questions about how Adecoagro is balancing growth, profitability, and capital structure. We’ll now examine how the ESOP-linked shelf...

Globus Medical, Inc. recently announced that Director John A. DeFord, PhD, resigned from its Board of Directors with immediate effect and will not stand for re-election at the June 3, 2026 Annual Meeting, leaving his role on the Nominating and Governance Committee. At the same time, new analyst coverage from Wells Fargo has drawn attention to Globus Medical’s execution, product portfolio expansion and updated 2026 outlook, sharpening focus on how governance and growth plans align. Against...

Diversified Energy recently announced a new share buyback program running through March 2027, targeting the repurchase of about 7.8 million shares and disclosing a completed buyback of 300,000 shares, while President and CFO Bradley Gray gifted 15,000 shares to family members, reducing his beneficial ownership to 212,790 shares. This combination of an expanded capital return plan and updated insider holdings offers fresh insight into how management is currently aligning with...

On March 18, 2026, Genuine Parts Company announced that Executive Vice President and Chief Information & Digital Officer Naveen Krishna had resigned, stepping down as an executive officer on April 1 while remaining until May 5 to support a transition, with his duties to be redistributed and no severance paid. The decision not to appoint a direct successor and instead spread Krishna’s responsibilities across existing leaders raises questions about how Genuine Parts will maintain momentum in...

Why AAR’s latest earnings and contracts matter for investors AAR (AIR) just reported third quarter results alongside higher full year sales guidance and two long term U.S. Air Force pallet contracts, giving investors fresh data points on earnings quality and revenue visibility. See our latest analysis for AAR. AAR’s latest earnings and U.S. Air Force pallet contracts come after a strong run, with the share price at $107.25 and a 90 day share price return of 26.91%, while the 1 year total...

Maze Therapeutics (MAZE) has drawn attention after recent trading saw the share price close at US$30.38. Returns over the past month and past 3 months have both shown double digit declines. See our latest analysis for Maze Therapeutics. The recent weakness, including a 4.19% one day and 36.75% seven day share price decline, comes after a very large 1 year total shareholder return of 166.02%. This suggests that momentum has cooled even as longer term holders remain well ahead. If Maze's swings...

National Fuel Gas (NYSE:NFG) entered into a new US$1.3b unsecured committed revolving credit facility with a group of major lenders. The new facility extends the company’s debt maturity profile to 2031 and amends prior credit agreements. Management plans to use the facility for repaying existing debt, general corporate purposes, and potential future investments. National Fuel Gas, a diversified energy company involved in natural gas exploration, production, gathering, and distribution, now...

Howmet Aerospace recently reported upbeat fiscal fourth-quarter results and raised its first-quarter profit guidance above analyst expectations, while also gaining visibility as one of Jim Cramer’s highlighted defense technology names. This combination of stronger-than-anticipated guidance and growing recognition for its role in supplying critical aerospace and defense components has sharpened investor focus on Howmet’s earnings power and industry positioning. Now we’ll explore how this...

If you are wondering whether Oracle's current share price reflects its true worth, you are not alone. This article is designed to help you frame that question clearly. The stock recently closed at US$139.66, with returns of 0.1% over 1 year, 55.8% over 3 years and 108.3% over 5 years. The year-to-date return sits at a 28.6% decline, and the last month shows a 3.9% decline after a 6.7% decline over the past week. Recent headlines have focused on Oracle's role as a large enterprise software...

Why Deckers Outdoor is on investors’ radar today Deckers Outdoor (DECK) is back in focus as investors weigh its recent share performance, including a roughly 20% decline over the past month and a decline of about 9% over the past three months, against its current fundamentals. See our latest analysis for Deckers Outdoor. At a share price of US$94.05, Deckers Outdoor has seen momentum cool recently, with a 7 day share price return of a 6.35% decline and a 30 day share price return of a 19.8%...

On March 19, 2026, Hovde Group upgraded SouthState Bank Corporation from Market Perform to Outperform, shortly after CEO John C. Corbett highlighted strong returns and a fourth-quarter 2025 repurchase of 2 million shares, alongside board approval for a new 5.56 million-share buyback program. This combination of an analyst upgrade and expanded repurchase authorization underscores external and internal confidence in SouthState’s capital deployment and longer-term prospects. Next, we’ll assess...

Why Cheniere Energy Partners Is Back in Focus With Qatari LNG exports disrupted by the Iran war, Cheniere Energy Partners (CQP) is drawing fresh attention as its Corpus Christi facility ramps up production to meet urgent global demand for liquefied natural gas. See our latest analysis for Cheniere Energy Partners. The recent Iran war related disruption to Qatari LNG exports has coincided with a 20.7% 3 month share price return and a 68.2% 3 year total shareholder return, signalling strong...

Recent share performance and business snapshot Fortive (FTV) shares have retreated over the past month and past 3 months, with returns of 8.9% and 4.0% respectively. This has prompted some investors to reassess the company’s fundamentals and recent financial profile. The group generates revenue of about US$4.16b and net income of roughly US$532.7m. Its operations are split between its Intelligent Operating Solutions and Advanced Healthcare Solutions segments across the United States, Asia...

Kymera Therapeutics recently reported past positive Phase 1b data for KT-621, its first-in-class oral STAT6 degrader in moderate-to-severe atopic dermatitis, showing deep STAT6 reduction, broad biomarker effects and encouraging clinical improvements after 28 days of once-daily dosing. The data, presented as a late-breaking oral session at the American Academy of Dermatology meeting, highlight how Kymera’s protein degradation platform may translate into biologics-like immune modulation using...

Flagstar Bank, N.A. recently announced that director Alessandro DiNello will not stand for re-election at the June 2026 annual meeting, while Eli H. Miller will join the board and serve on the Risk Assessment and Technology and Operations Committees, alongside the appointment of five senior technology leaders to advance its S2 digital transformation program. Together, these board and technology leadership changes suggest a sharpened focus on governance, risk management, and technology...

Carvana (CVNA) has drawn fresh attention after proposing a 5-for-1 stock split tied to shareholder approval, aimed at helping long-term employees build ownership, alongside renewed analyst support for its retail unit growth prospects. See our latest analysis for Carvana. At a share price of US$302.04, Carvana shows strong long term momentum with a very large 3 year total shareholder return. Recent share price moves, including a 30% 90 day decline and 25% year to date decline, point to cooling...

JonnyPops is rolling out its Organic Water Pops to more than 1,800 Albertsons Companies (ACI) stores nationwide, expanding Albertsons frozen assortment with branded better-for-you treats aimed at families shopping the frozen aisle. See our latest analysis for Albertsons Companies. Albertsons Companies’ recent news on expanding better-for-you frozen treats comes against a backdrop of a 4.64% 1 month share price decline and a 1 year total shareholder return fall of 18.59%, while the 5 year...